Jason Zemcik is the Product Director for TrialCard’s TC Synapse suite of compliance and risk management solutions, which encompasses co-pay program fraud monitoring and detection, co-pay accumulator mitigation strategies, and government exclusion and anti-kickback safeguards.

Jason joined TrialCard in 2011 and has held roles in Program Management, Data Analytics, Marketing, and Operations. He holds a Project Management Professional (PMP) certification and is a member of the National Health Care Anti-Fraud Association.

Prior to joining TrialCard, Jason served seven years as a United States Army officer, deploying to both Iraq and Afghanistan.

Jason is a graduate of the United States Military Academy at West Point where he earned a BS in Legal Studies with a minor in Systems Engineering.

Rick Fry, who joined TrialCard in 2013, leads TrialCard’s Client Services team. He partners with a cross-functional team of IT, analytics, marketing, and business development professionals to deliver best-in-class patient support programs for TrialCard’s biopharmaceutical clients. Prior to this role, Rick led several operations teams supporting TrialCard’s claims processing, operations management, and production and fulfillment. Rick is an active participant in the National Council for Prescription Drug Programs (NCPDP), where he represents the interests of TrialCard and its customers.

Rick also served for eight years in the United States Air Force as a Financial Management Officer. In this role, Rick managed multimillion-dollar operational programs and supported multi-year procurement programs valued at over $80 billion.

Rick holds a BS in Management from the United States Air Force Academy and a Master of Science in Cost Analysis from the Air Force Institute of Technology.

Dec 2015-Present: Director Patient Access and Reimbursement Services – Eisai
Dec 2013-Dec 2015: Deputy Director Patient Access Services - Bayer
Nov 2011-Nov 2013: Deputy Director Pricing and Reimbursement and Patient Assistance -Bayer
Jun 2009-Oct 2011: Manager Pricing and Reimbursement and Patient Assistance-Bayer
Jan 2008-May 2009: Brand Manager Oncology Marketing Leukine-Berlex/Bayer
Nov 2004-Dec 2007: Senior Oncology Specialty Representative-Berlex
April 2003-Oct 2004: Hospital Sales Consultant –Pfizer
Sept 1998-March 2003: Primary Care Representative G.D. Searle/Pharmacia
August 1972-Aug 1998: United States Army Special Forces (Green Beret) Sergeant Major(retired)

Current job description: Currently the Director of Patient Access and Reimbursement Services at Eisai. Currently responsible for 7 Patient Support Programs to include Patient Assistance Programs Eisai’s portfolio. He provides research analysis and intelligence to the Oncology, Neurology and Metabolic Business Units on public policy, reimbursement and coverage issues, develops strategies, minimizes impact of competitors, mitigates adverse effects and identified opportunities to favorably position Eisai Inc. and their products.

Education: Undergrad- Business Administration from Mary Baldwin College

Thomas has a BS in Biology from UC Riverside (Magna Cum Laude) and a MS in Business of Bioscience from Keck Graduate Institute. He has worked across Managed Markets at Gilead Sciences in Commercial Rebates, Strategy, and Analytics. Prior to Gilead, he was a management consultant with top pharma clients in the SF Bay Area. Projects included new product launches, process optimization, and market strategy. He is currently leading forensic analytics and investigations for the Data Forensics team at Gilead.

Amy Niles is Vice President of External Relations for the Patient Access Network (PAN) Foundation. The PAN Foundation is a national nonprofit that helps underinsured people with life-threatening, chronic and rare diseases get the medications and treatment they need by paying for their out-of-pocket costs and advocating for improved access and affordability. Amy oversees alliances with patient groups and provider organizations, and spearheads PAN’s advocacy and public policy initiatives.

Prior to joining PAN, Amy led outreach programs for Together Rx Access, a prescription savings program for the uninsured. Prior to Together Rx Access, Amy was President and CEO of the National Women’s Health Resource Center (NWHRC), now known as HealthyWomen, for well over a decade. Serving as an independent clearinghouse for women’s health information, Amy grew the organization from an idea to a national resource.

Amy began her career in health care administration in hospitals in New York and Washington, DC. She holds a master’s degree in business administration from Baruch College, City University of New York. She graduated the University of Rochester with an undergraduate degree in biology.

Kim Calder has been with the National Multiple Sclerosis Society since 2003, currently serving as Senior Director of Health Policy. In this capacity, Kim leads the Society’s policy analysis on healthcare reform work on behalf of with MS at the federal and state levels. Along with her colleagues, she also supports a policy agenda based on the organization’s Make MS Medications Accessible campaign which calls on all stakeholders to work together to make medications affordable, with transparency across the drug supply and delivery systems, and the process for accessing medications simple for the people who need them.

Before joining the Society, Kim held policy and leadership positions at Cancer Care Inc., the National Alliance of Breast Cancer Organizations, and the American Cancer Society. She has served on the governing boards of Empire Blue Cross and Blue Shield and the American Pain Society, and on advisory councils to the National Cancer Institute, US Food & Drug Administration, and the National Association of Insurance Commissioners, and is currently a leader in the ‘All Copays Count’ Coalition, which seeks to eliminate the practice of copay accumulator programs.

Kollet is responsible for project leadership, analysis and the development of NHF’s healthcare payer education strategies, policies and programs, including the Comprehensive Care Sustainability Collaborative (CCSC). Prior to her tenure at NHF, Kollet served as the Executive Director of the Bleeding & Clotting Disorders Institute in Peoria IL, a federally recognized Hemophilia Treatment Center(HTC) of Excellence, where she developed and grew an inhouse specialty pharmacy program that became one of the larger programs in the country. Kollet has also served on the Hemophilia Alliance Executive Board of Directors, served as the chair of the national payer subcommittee and sat on the Illinois Hemophilia Advisory board.

With hemophilia ranking #12 of 20 for highest cost catastrophic claims, #9 for reported high cost claims for stop loss carriers and #8 of 10 highest cost claims for jumbo employer sponsored health plans ; Kollet strongly believes that the stage is set for all parties who share in the cost risks associated with rare chronic disorders, to change their current practice of giving away their healthcare brainpower to those who might have experience with specialty pharmacy dispensation for these chronic rare diseases, without at least entering into dialogue with those that are the experts in managing this patient population.

Dialogue that involves the development of plan interventions that do not require a regulatory fix or legislation to be passed, to begin to find success in lowering overall spend, without risking outcomes. Kollet and her colleagues on the payer team at the National Hemophilia Foundation are dedicated to facilitating payer/provider value-based conversations aimed at educating those exposed to high cost claimants about the federally recognized care management resources that are available; providing transparent tools to analyze where significant savings CAN occur; and identifying data that will enable the development of strategies that will lower costs and improve outcomes.

Carl Schmid has been with The AIDS Institute since February 2004, leading the Institute’s federal policy work.

Schmid helps lead the HIV and hepatitis communities’ advocacy efforts in Washington DC to ensure domestic programs are based on sound public policy and fully funded. He is a Convening Group member of the Federal AIDS Policy Partnership and co-chairs its AIDS Budget and Appropriations Coalition.

As part of the Institute’s work in advocating for people with HIV and hepatitis, Schmid works with other patient and disease groups to ensure that patients have access to quality, affordable health care. In January 2018, Schmid was appointed as a consumer representative to the National Association of Insurance Commissioners.

In December 2018, Schmid was appointed Co-Chair of the Presidential Advisory Council on HIV/AIDS.

Schmid earned a B.A. in Public Affairs and a M.B.A. in International Affairs from the George Washington University.